Genmab A/S (NASDAQ:GMAB) Upgraded at Leerink Partnrs

Genmab A/S (NASDAQ:GMAB) was upgraded by equities researchers at Leerink Partnrs from a “hold” rating to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

A number of other equities analysts have also weighed in on GMAB. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. BMO Capital Markets reiterated an “outperform” rating and set a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Finally, Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a report on Thursday. Four analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.17.

Genmab A/S Stock Up 6.2 %

NASDAQ GMAB opened at $20.92 on Thursday. The firm has a market cap of $13.84 billion, a P/E ratio of 20.31, a P/E/G ratio of 0.54 and a beta of 0.96. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.88. The business’s 50-day moving average price is $20.68 and its 200 day moving average price is $23.21.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. As a group, analysts anticipate that Genmab A/S will post 1.25 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its holdings in shares of Genmab A/S by 7.8% in the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock worth $40,199,000 after acquiring an additional 139,722 shares during the period. First Trust Advisors LP boosted its position in Genmab A/S by 18.0% during the fourth quarter. First Trust Advisors LP now owns 1,644,288 shares of the company’s stock worth $34,316,000 after purchasing an additional 251,241 shares in the last quarter. Brandywine Global Investment Management LLC acquired a new stake in Genmab A/S in the fourth quarter valued at $33,804,000. Marshall Wace LLP increased its position in shares of Genmab A/S by 162.2% in the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock valued at $23,422,000 after buying an additional 694,243 shares in the last quarter. Finally, Two Sigma Advisers LP raised its stake in shares of Genmab A/S by 84.1% during the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after buying an additional 280,900 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.